{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:37:11Z","timestamp":1785926231880,"version":"3.56.0"},"reference-count":44,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R02118X\/1"],"award-info":[{"award-number":["MR\/R02118X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["107743"],"award-info":[{"award-number":["107743"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,12,15]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Several licensed and investigational vaccines have lower efficacy, and induce impaired immune responses, in low-income versus high-income countries and in rural, versus urban, settings. Understanding these population differences is essential to optimising vaccine effectiveness in the tropics. We suggest that repeated exposure to and immunomodulation by chronic helminth infections partly explains population differences in vaccine response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>We have designed an individually randomised, parallel group trial of intensive versus standard praziquantel (PZQ) intervention against schistosomiasis, to determine effects on vaccine response outcomes among school-going adolescents (9\u201317 years) from rural<jats:italic>Schistosoma mansoni<\/jats:italic>-endemic Ugandan islands. Vaccines to be studied comprise BCG on day \u2018zero\u2019; yellow fever, oral typhoid and human papilloma virus (HPV) vaccines at week 4; and HPV and tetanus\/diphtheria booster vaccine at week 28. The intensive arm will receive PZQ doses three times, each 2 weeks apart, before BCG immunisation, followed by a dose at week 8 and quarterly thereafter. The standard arm will receive PZQ at week 8 and 52. We expect to enrol 480 participants, with 80% infected with<jats:italic>S. mansoni<\/jats:italic>at the outset.<\/jats:p><jats:p>Primary outcomes are BCG-specific interferon-\u03b3 ELISpot responses 8 weeks after BCG immunisation and for other vaccines, antibody responses to key vaccine antigens at 4 weeks after immunisation. Secondary analyses will determine the effects of intensive anthelminthic treatment on correlates of protective immunity, on waning of vaccine response, on priming versus boosting immunisations and on<jats:italic>S. mansoni<\/jats:italic>infection status and intensity. Exploratory immunology assays using archived samples will enable assessment of mechanistic links between helminths and vaccine responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>Ethics approval has been obtained from relevant ethics committes of Uganda and UK. Results will be shared with Uganda Ministry of Health, relevant district councils, community leaders and study participants. Further dissemination will be done through conference proceedings and publications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"ISRCTN60517191\">ISRCTN60517191<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2020-040426","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T01:44:47Z","timestamp":1613526287000},"page":"e040426","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the \u2018POPulation differences in VACcine responses\u2019 (POPVAC) programme"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"isrctn60517191","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4062-9105","authenticated-orcid":false,"given":"Gyaviira","family":"Nkurunungi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludoviko","family":"Zirimenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacent","family":"Nassuuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Natukunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prossy N","family":"Kabuubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Niwagaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Oduru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kabami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Amongin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mutebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milly","family":"Namutebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Zziwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Amongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ninsiima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Onen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Akello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Sewankambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Kiwanuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kizindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kaweesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Cose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"2024101905112348000_11.2.e040426.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.04.080"},{"key":"2024101905112348000_11.2.e040426.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92348-9"},{"key":"2024101905112348000_11.2.e040426.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08353-8"},{"key":"2024101905112348000_11.2.e040426.4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75429"},{"key":"2024101905112348000_11.2.e040426.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.05.042"},{"key":"2024101905112348000_11.2.e040426.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-014-0660-7","article-title":"Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A","volume":"14","author":"Tanner","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2024101905112348000_11.2.e040426.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30104-4"},{"key":"2024101905112348000_11.2.e040426.8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal","volume":"219","author":"Venkatraman","year":"2019","journal-title":"J Infect Dis"},{"key":"2024101905112348000_11.2.e040426.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.05.023"},{"key":"2024101905112348000_11.2.e040426.10","doi-asserted-by":"publisher","DOI":"10.1086\/522010"},{"key":"2024101905112348000_11.2.e040426.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.067"},{"key":"2024101905112348000_11.2.e040426.12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal","volume":"219","author":"Venkatraman","year":"2019","journal-title":"J Infect Dis"},{"key":"2024101905112348000_11.2.e040426.13","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.2.672-678.2002"},{"key":"2024101905112348000_11.2.e040426.14","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0606407"},{"key":"2024101905112348000_11.2.e040426.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.07.007"},{"key":"2024101905112348000_11.2.e040426.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70771-6"},{"key":"2024101905112348000_11.2.e040426.17","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939699"},{"key":"2024101905112348000_11.2.e040426.18","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad5872","article-title":"Viral immunity. Transkingdom control of viral infection and immunity in the mammalian intestine","volume":"351","author":"Pfeiffer","year":"2016","journal-title":"Science"},{"key":"2024101905112348000_11.2.e040426.19","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.10-0397"},{"key":"2024101905112348000_11.2.e040426.20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001830"},{"key":"2024101905112348000_11.2.e040426.21","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00772-16","article-title":"Microbial translocation associated with an acute-phase response and elevations in MMP-1, HO-1, and proinflammatory cytokines in Strongyloides stercoralis infection","volume":"85","author":"Rajamanickam","year":"2017","journal-title":"Infect Immun"},{"key":"2024101905112348000_11.2.e040426.22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/trstmh\/trx010","article-title":"A life without worms","volume":"111","author":"Sanya","year":"2017","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024101905112348000_11.2.e040426.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.083"},{"key":"2024101905112348000_11.2.e040426.24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01446.x"},{"key":"2024101905112348000_11.2.e040426.25","doi-asserted-by":"publisher","DOI":"10.1086\/315837"},{"key":"2024101905112348000_11.2.e040426.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007157","article-title":"Effect of Schistosoma mansoni infection and its treatment on antibody responses to measles catch-up immunisation in pre-school children: a randomised trial","volume":"13","author":"Tweyongyere","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2024101905112348000_11.2.e040426.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2024101905112348000_11.2.e040426.28","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/cid\/ciy761","article-title":"The impact of intensive versus standard anthelminthic treatment on allergy-related outcomes, helminth infection intensity, and Helminth-related morbidity in lake Victoria fishing communities, Uganda: results from the LaVIISWA cluster-randomized trial","volume":"68","author":"Sanya","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024101905112348000_11.2.e040426.29","unstructured":"WHO . Adolescent health research priorities: report of a technical consultation 2015. Available: http:\/\/apps.who.int\/iris\/bitstream\/10665\/203564\/1\/WHO_FWC_MCA_15_07_eng.pdf?ua=1 [Accessed 17 May 2019]."},{"key":"2024101905112348000_11.2.e040426.30","doi-asserted-by":"publisher","DOI":"10.1111\/all.12867"},{"key":"2024101905112348000_11.2.e040426.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2004.06.006"},{"key":"2024101905112348000_11.2.e040426.32","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10"},{"key":"2024101905112348000_11.2.e040426.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005180","article-title":"Schistosoma mansoni infection can jeopardize the duration of protective levels of antibody responses to immunizations against hepatitis B and tetanus toxoid","volume":"10","author":"Riner","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2024101905112348000_11.2.e040426.34","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-015-0857-7"},{"key":"2024101905112348000_11.2.e040426.35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11290"},{"key":"2024101905112348000_11.2.e040426.36","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0203"},{"key":"2024101905112348000_11.2.e040426.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2024101905112348000_11.2.e040426.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2024101905112348000_11.2.e040426.39","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5RI0315-096R"},{"key":"2024101905112348000_11.2.e040426.40","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.676"},{"key":"2024101905112348000_11.2.e040426.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003995","article-title":"CD4+CD25hiFOXP3+ regulatory T cells and cytokine responses in human schistosomiasis before and after treatment with praziquantel","volume":"9","author":"Schmiedel","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2024101905112348000_11.2.e040426.42","doi-asserted-by":"publisher","DOI":"10.1086\/344352"},{"key":"2024101905112348000_11.2.e040426.43","doi-asserted-by":"publisher","DOI":"10.1038\/15169"},{"key":"2024101905112348000_11.2.e040426.44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/21645515.2015.1009814","article-title":"Clinically feasible approaches to potentiating cancer cell-based immunotherapies","volume":"11","author":"Seledtsov","year":"2015","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-040426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T12:14:13Z","timestamp":1729340053000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-040426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,16]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjopen-2020-040426"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-040426","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}